Public Employees Retirement Association of Colorado Sells 759 Shares of Illumina, Inc. (NASDAQ:ILMN)

Public Employees Retirement Association of Colorado trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 4.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,436 shares of the life sciences company’s stock after selling 759 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Illumina were worth $1,716,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Bouvel Investment Partners LLC boosted its holdings in shares of Illumina by 1.3% during the 1st quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock valued at $899,000 after purchasing an additional 84 shares during the last quarter. UMB Bank n.a. grew its holdings in Illumina by 7.0% during the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock valued at $140,000 after buying an additional 88 shares in the last quarter. Gulf International Bank UK Ltd increased its stake in Illumina by 0.7% in the 1st quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock worth $1,862,000 after acquiring an additional 98 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Illumina by 4.9% during the 1st quarter. GAMMA Investing LLC now owns 2,258 shares of the life sciences company’s stock worth $310,000 after acquiring an additional 105 shares in the last quarter. Finally, Texas Permanent School Fund Corp boosted its position in shares of Illumina by 0.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 32,818 shares of the life sciences company’s stock valued at $4,507,000 after acquiring an additional 114 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ILMN shares. Royal Bank of Canada reissued an “outperform” rating and issued a $242.00 price objective on shares of Illumina in a research note on Wednesday, August 14th. Scotiabank reduced their price objective on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research note on Thursday, August 15th. Evercore ISI lowered their price objective on Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a research note on Tuesday, June 11th. Argus raised Illumina from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a research report on Wednesday, August 28th. Finally, Robert W. Baird raised their price target on Illumina from $119.00 to $124.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $151.05.

Illumina Price Performance

NASDAQ ILMN opened at $130.10 on Tuesday. The company has a market cap of $20.72 billion, a PE ratio of -15.96 and a beta of 1.15. The firm’s 50 day moving average price is $125.52 and its 200-day moving average price is $120.42. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $148.19.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.24. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The business’s revenue for the quarter was down 5.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.32 EPS. Sell-side analysts forecast that Illumina, Inc. will post 3.62 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.